3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia
2
Tuberous Sclerosis
1
Tourette Syndrome
1
Tic Disorders
1
Preleukemia
1
Neurodevelopmental Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Hematologic Diseases
1
Glioblastoma
1
Fragile X Syndrome
1
DiGeorge Syndrome
1
Depression
1
Cytopenia
1
Bone Marrow Diseases
1
Autistic Disorder
1
Autism Spectrum Disorder
1
Attention Deficit Disorder with Hyperactivity
1
Anxiety Disorders
1
Anemia
1
22q11 Deletion Syndrome
1
Interventions
Epoetin Alfa
53
Darbepoetin alfa
38
epoetin beta
12
ferric carboxymaltose
11
Lenalidomide
5
Cyclophosphamide
5
luspatercept
4
fludarabine phosphate
4
fludarabine
4
Erythropoietin
4
Cyclosporine
4
Cisplatin
4
Busulfan
4
Blood Transfusion
4
ACE-011
4
peginesatide
3
iron isomaltoside 1000
3
hematide
3
ferrous sulfate
3
ferric gluconate
3
Radiotherapy
3
Iron-Dextran Complex
3
Filgrastim
3
Ferric Oxide, Saccharated
3
Biopsy
3
Antilymphocyte Serum
3
thymoglobulin
2
telapristone acetate
2
ruxolitinib
2
ferrous fumarate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Anemia
×
Sertraline
×
Clear all
NCT02452983
2022-06-02
SS1
Baylor College of Medicine
Phase 1
Terminated
14 enrolled